secwatch / observer
8-K filed March 16, 2026, 7:59 PM ET ticker ANRO CIK 0001999480
other material confidence high sentiment positive materiality 0.85

Alto Neuroscience raises $120M via PIPE to fund ALTO-207 Phase 3 in TRD

Alto Neuroscience, Inc.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Alto Neuroscience, Inc. issued pre-funded warrants to purchase 3,100,000 shares of Common Stock of warrant to institutional investors for purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant.

Security
warrant
Shares
pre-funded warrants to purchase 3,100,000 shares of Common Stock
Purchaser
institutional investors
Consideration
purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant
Exact text from the filing
to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Alto Neuroscience, Inc. issued 2,900,000 shares of common stock to institutional investors for $20.00 per share.

Security
common stock
Shares
2,900,000 shares
Purchaser
institutional investors
Consideration
$20.00 per share
Exact text from the filing
Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares. The purchase price per share of Common Stock is $20.00 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant. The Company anticipates receiving
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Alto Neuroscience, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $120.0 million (effective 2026-03-16).

Action
entry
Agreement
equity purchase
Counterparty
certain institutional investors
Value
approximately $120.0 million
Effective
2026-03-16
Exact text from the filing
On March 16, 2026, Alto Neuroscience, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.
View on SEC.gov

Browse all equity issuances →

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-027953
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.